Biblio

Export 468 results:
[ Author(Desc)] Keyword Title Type Year
Filters: Keyword is Alzheimer Disease  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
F
C. Ferrari, Lombardi, G., Polito, C., Lucidi, G., Bagnoli, S., Piaceri, I., Nacmias, B., Berti, V., Rizzuto, D., Fratiglioni, L., and Sorbi, S., “Alzheimer's Disease Progression: Factors Influencing Cognitive Decline.”, J Alzheimers Dis, vol. 61, no. 2, pp. 785-791, 2018.
C. E. Fischer, Qian, W., Schweizer, T. A., Millikin, C. P., Ismail, Z., Smith, E. E., Lix, L. M., Shelton, P., and Munoz, D. G., “Lewy Bodies, Vascular Risk Factors, and Subcortical Arteriosclerotic Leukoencephalopathy, but not Alzheimer Pathology, are Associated with Development of Psychosis in Alzheimer's Disease.”, J Alzheimers Dis, vol. 50, no. 1, pp. 283-95, 2016.
M. E. Flanagan, Larson, E. B., Walker, R. L., C Keene, D., Postupna, N., Cholerton, B., Sonnen, J. A., Dublin, S., Crane, P. K., and Montine, T. J., “Associations between Use of Specific Analgesics and Concentrations of Amyloid-β 42 or Phospho-Tau in Regions of Human Cerebral Cortex.”, J Alzheimers Dis, vol. 61, no. 2, pp. 653-662, 2018.
H. Florian, Meier, A., Gauthier, S., Lipschitz, S., Lin, Y., Tang, Q., Othman, A. A., Robieson, W. Z., and Gault, L. M., “Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1237-47, 2016.
M. T. Fodero-Tavoletti, Okamura, N., Furumoto, S., Mulligan, R. S., Connor, A. R., McLean, C. A., Cao, D., Rigopoulos, A., Cartwright, G. A., O'Keefe, G., Gong, S., Adlard, P. A., Barnham, K. J., Rowe, C. C., Masters, C. L., Kudo, Y., Cappai, R., Yanai, K., and Villemagne, V. L., “18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease.”, Brain, vol. 134, no. Pt 4, pp. 1089-100, 2011.
K. C. Fraser, Meltzer, J. A., and Rudzicz, F., “Linguistic Features Identify Alzheimer's Disease in Narrative Speech.”, J Alzheimers Dis, vol. 49, no. 2, pp. 407-22, 2016.
K. Steen Frederiksen, Gjerum, L., Waldemar, G., and Hasselbalch, S. Gregers, “Effects of Physical Exercise on Alzheimer's Disease Biomarkers: A Systematic Review of Intervention Studies.”, J Alzheimers Dis, vol. 61, no. 1, pp. 359-372, 2018.
G
A. Gabelle, Gutierrez, L. - A., Dartigues, J. - F., Ritchie, K., Touchon, J., and Berr, C., “Palmomental Reflex a Relevant Sign in Early Alzheimer's Disease Diagnosis?”, J Alzheimers Dis, vol. 49, no. 4, pp. 1135-41, 2016.
A. José Gabriel, Almeida, M. Rosário, Ribeiro, M. Helena, Carneiro, D., Valério, D., Pinheiro, A. Cristina, Pascoal, R., Santana, I., and Baldeiras, I., “Influence of Butyrylcholinesterase in Progression of Mild Cognitive Impairment to Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 3, pp. 1097-1105, 2018.
D. R. Galasko, Grill, J. D., Lingler, J. H., and Heidebrink, J. L., “A Blood Test for Alzheimer's Disease: It's about Time or Not Ready for Prime Time?”, J Alzheimers Dis, vol. 90, no. 3, pp. 963-966, 2022.
M. Gallucci, Spagnolo, P., Aricò, M., and Grossi, E., “Predictors of Response to Cholinesterase Inhibitors Treatment of Alzheimer's Disease: Date Mining from the TREDEM Registry.”, J Alzheimers Dis, vol. 50, no. 4, pp. 969-79, 2016.
L. Gao, Cui, Z., Shen, L., and Ji, H. - F., “Shared Genetic Etiology between Type 2 Diabetes and Alzheimer's Disease Identified by Bioinformatics Analysis.”, J Alzheimers Dis, vol. 50, no. 1, pp. 13-7, 2016.
A. J García-Casal, Goñi-Imizcoz, M., M Perea-Bartolomé, V., Soto-Pérez, F., Smith, S. Jane, Calvo-Simal, S., and Franco-Martín, M., “The Efficacy of Emotion Recognition Rehabilitation for People with Alzheimer's Disease.”, J Alzheimers Dis, vol. 57, no. 3, pp. 937-951, 2017.
S. L. Gardener, Rainey-Smith, S. R., and Martins, R. N., “Diet and Inflammation in Alzheimer's Disease and Related Chronic Diseases: A Review.”, J Alzheimers Dis, vol. 50, no. 2, pp. 301-34, 2016.
B. E. Gavett, John, S. E., Gurnani, A. S., Bussell, C. A., and Saurman, J. L., “The Role of Alzheimer's and Cerebrovascular Pathology in Mediating the Effects of Age, Race, and Apolipoprotein E Genotype on Dementia Severity in Pathologically-Confirmed Alzheimer's Disease.”, J Alzheimers Dis, vol. 49, no. 2, pp. 531-45, 2016.
S. L. C. Geijselaers, Aalten, P., Ramakers, I. H. G. B., De Deyn, P. Paul, Heijboer, A. C., Koek, H. L., OldeRikkert, M. G. M., Papma, J. M., Reesink, F. E., Smits, L. L., Stehouwer, C. D. A., Teunissen, C. E., Verhey, F. R. J., van der Flier, W. M., and Biessels, G. Jan, “Association of Cerebrospinal Fluid (CSF) Insulin with Cognitive Performance and CSF Biomarkers of Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 1, pp. 309-320, 2018.
S. Gelman, Palma, J., Tombaugh, G., and Ghavami, A., “Differences in Synaptic Dysfunction Between rTg4510 and APP/PS1 Mouse Models of Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 1, pp. 195-208, 2018.
R. Gil and Arroyo-Anlló, E. M., “Alzheimer's Disease and Face Masks in Times of COVID-19.”, J Alzheimers Dis, vol. 79, no. 1, pp. 9-14, 2021.
D. A. Gimbel, Nygaard, H. B., Coffey, E. E., Gunther, E. C., Laurén, J., Gimbel, Z. A., and Strittmatter, S. M., “Memory impairment in transgenic Alzheimer mice requires cellular prion protein.”, J Neurosci, vol. 30, no. 18, pp. 6367-74, 2010.
L. GjØra, Strand, B. Heine, Bergh, S., Borza, T., Brækhus, A., Engedal, K., Johannessen, A., Kvello-Alme, M., Krokstad, S., Livingston, G., Matthews, F. E., Myrstad, C., Skjellegrind, H., Thingstad, P., Aakhus, E., Aam, S., and Selbæk, G., “Current and Future Prevalence Estimates of Mild Cognitive Impairment, Dementia, and Its Subtypes in a Population-Based Sample of People 70 Years and Older in Norway: The HUNT Study.”, J Alzheimers Dis, vol. 79, no. 3, pp. 1213-1226, 2021.
C. E. Gleason, Norton, D., Anderson, E. D., Wahoske, M., Washington, D. T., Umucu, E., Koscik, R. L., N Dowling, M., Johnson, S. C., Carlsson, C. M., and Asthana, S., “Cognitive Variability Predicts Incident Alzheimer's Disease and Mild Cognitive Impairment Comparable to a Cerebrospinal Fluid Biomarker.”, J Alzheimers Dis, vol. 61, no. 1, pp. 79-89, 2018.
O. Godefroy, Bakchine, S., Verny, M., Delabrousse-Mayoux, J. - P., Roussel, M., and Pere, J. - J., “Characteristics of Alzheimer's Disease Patients with Severe Executive Disorders.”, J Alzheimers Dis, vol. 51, no. 3, pp. 815-25, 2016.
T. E. Golde, Schneider, L. S., and Koo, E. H., “Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift.”, Neuron, vol. 69, no. 2, pp. 203-13, 2011.
J. J. Gomar, Conejero-Goldberg, C., Davies, P., and Goldberg, T. E., “Anti-Correlated Cerebrospinal Fluid Biomarker Trajectories in Preclinical Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1085-97, 2016.
E. Gómez-Tortosa, Ruggiero, M., Sainz, M. José, Villarejo-Galende, A., Prieto-Jurczynska, C., Pérez, B. Venegas, Ordás, C., Agüero, P., Guerrero-López, R., and Pérez-Pérez, J., “SORL1 Variants in Familial Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 4, pp. 1275-1281, 2018.

Pages